Cover Image
市場調查報告書

黑色素瘤 :治療藥的預測與全球市場分析

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 334909
出版日期 內容資訊 英文 377 Pages
訂單完成後即時交付
價格
Back to Top
黑色素瘤 :治療藥的預測與全球市場分析 PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2023
出版日期: 2015年04月05日 內容資訊: 英文 377 Pages
簡介

黑色素瘤是皮膚癌中最有致命性的,侵略性最高。全球主要8個國家的黑色素瘤治療藥的市場,從2013年的13億4000萬美元,預計到2023年增加4倍達5億64000萬美元(其間年複合成長率(CAGR)為15.5%)。這個急速成長的原因之一,為PD-1標的單株抗體和BRAF/MEK抑制劑的配合之最新銳且高價格的治療藥的認證、普及。還有,預計今後含查核點免疫療法的藥物類別 (野生型BRAF/免疫陽性患者治療藥) 將佔市場67%。另一方面,今後的課題為,與目前主流的治療方法 (免疫療法、BRAF免疫標靶治療等) 的競爭,及開拓還未診斷的患者,免疫/標靶治療的新組合方法的開發等。

本報告提供全球的黑色素瘤治療藥市場現況與未來展望相關分析、調查與疾病概要和今後的流行病學的預測、在主要國家的預防體性、主要企業簡介代表性產品、市場未滿足需求與未來機會、現在臨床實驗中的開發中產品的資訊、今後的市場規模及影響要素等。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理
    • 病因
    • 病理生理學、病歷
    • 黑色素瘤的生物標記
  • 臨床階段
  • 症狀
  • 預後
  • 生活品質(QoL)

第4章 流行病學

  • 疾病的背景情況
  • 風險要素和共生病症
  • 全球各地的趨勢
    • 美國
    • 歐洲主要5個國家
    • 日本、澳洲
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 流行病學的預測(今後11年份)
    • 黑色素瘤的發病數量(總數)
    • 黑色素瘤的發病數量(各年齡)
    • 黑色素瘤的發病數量(男女)
    • 黑色素瘤的年齡已調整的發病率
    • 診斷時的分期階段
    • 盛行率黑色素瘤皮膚癌症的5年
    • 黑色素瘤皮膚癌症的5年盛行率 (遺傳異常造成)
  • 議論
    • 流行病學上的預測、考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 診斷概要
  • 治療概要
    • 侷限性黑色素瘤:階段0∼IIC
    • 局部性黑色素瘤:階段IIIA∼IIIC
    • 不能切除/轉移性黑色素瘤:階段III∼IV
  • 美國
    • 診斷
    • 臨床診療
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 澳洲

第6章 競爭環境

  • 概要
  • 以干擾素為基礎的輔助性治療
    • Roferon-A (干擾素α2a)
    • Intron A (干擾素α2b)
    • Sylatron (Pegylated interferon-alpha2b)
  • 免疫查核點抑制劑
    • Yervoy (Ipilimumab)
    • Opdivo (noborumabu)
    • Keytruda (penburorizumabu)
  • BRAF突然變異標靶治療
    • Zelboraf (Vemurafenib)
    • Tafinlar (daburafenibu)
    • Mekinist (toramechinibu)
  • 其他治療層級

第7章 市場機會及未滿足需求

  • 概要
  • 野生型BRAF患者的治療選擇
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 對PD-1免疫療法無反應者的治療
  • 對高風險、可切除的黑色素瘤的輔助性治療
  • 對腦轉移的有效治療
  • 對免疫療法的治療反應的預見標記

第8章 開發平台評估

  • 概要
  • 臨床實驗中有前途的醫藥品
  • RAF/RAS/MEK途徑標靶治療
    • Cobimetinib (GDC-0973)
    • Encorafenib (LGX818)
    • Binimetinib (MEK162)
  • 免疫相關療法
    • Talimogene Laherparepvec
    • Eltrapuldencel-T (NSB20)
    • Seviprotimut-L (POL-103A)
    • PV-10
  • 開發初期階段的潛力藥物
    • PI3k/Akt/mTOR途徑標靶治療
    • 細胞週期查核點抑制劑
    • 下一代型的BRAF抑制劑
    • 抗體-藥物結合體
  • 開發中的其他藥劑

第9章 現在、未來市場參與企業

  • 概要
  • 企業策略概要
  • 企業簡介
    • Bristol-Myers Squibb
    • Novartis
    • Roche
    • Merck

第10章 市場預測

  • 全球市場
    • 市場預測
    • 市場促進、阻礙因素:全球的課題
  • 美國
    • 市場預測
    • 近幾年主要的事件
    • 市場促進、阻礙因素
  • 歐洲主要5個國家
    • 市場預測
    • 近幾年主要的事件
    • 市場促進、阻礙因素:法國
    • 市場促進、阻礙因素:德國
    • 市場促進、阻礙因素:義大利
    • 市場促進、阻礙因素:西班牙
    • 市場促進、阻礙因素:英國
  • 日本
  • 澳洲

第11章 附錄

圖表一覽

目錄
Product Code: GDHC104PIDR

Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies. GlobalData estimates the 2013 sales for melanoma at approximately $1.34 billion across the 8MM covered in this report. The market will increase by four-fold over the forecast period, reaching $5.64 billion in 2023 at a CAGR of 15.5%. This growth will be driven by an increase in melanoma incident cases as well as the approval and uptake of premium-priced products, such as PD-1-targeting mAbs and BRAF/MEK inhibitor combinations. GlobalData expects, by the end of the forecast period, the checkpoint immunotherapy drug class to dominate the melanoma market (including both BRAF wild-type and mutation-positive patient segments) with an overall 67% share of the melanoma market.

The melanoma pipeline is strong; however, GlobalData expects none of these drugs to have a major impact on the overall melanoma market, as the market is crowded with effective immunotherapies and BRAF mutation-targeted agents. The challenge for new entrants into the melanoma market is to find patient populations that are currently underserved. One of the opportunities for the companies is to work cooperatively to develop novel combinations of immuno/targeted-therapies.

Highlights

Key Questions Answered

  • The melanoma space is filled with the excitement of recently approved anti-PD-1 immunotherapies, which are expected to revolutionize the treatment landscape. What will be the impact of these newly approved drugs and their projected label expansions on the melanoma sales?
  • As the melanoma market is getting increasingly crowded with multiple anti-PD-1 immunotherapies and BRAF mutation-targeted agents, opportunities for new entrants become limited. What R&D strategies are being used by drug makers to remain competitive?
  • The survival of patients with metastatic melanoma remains short, especially for those who do not response to anti-PD-1 immunotherapies. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the melanoma market?

Key Findings

  • One of the main drivers of the enormous expansion of the gout market will be the launch of premium-priced metastatic therapies, such as anti-PD-1 immunotherapy and BRAF/MEK inhibitor combinations. These drugs will extend treatment duration and replace cheaper, generic, chemotherapy regimens.
  • Another strong driver will be the label extension of current therapies into the new settings; for example, PD-1s will garner label extension for the first-line treatment in 2015-16, and the metastatic brands are expected to be approved in the adjuvant setting in the second half of the forecast period.
  • Companies are focusing on the development of combination immunotherapies, trying to improve the response rate and response duration of drugs.
  • One of the largest unmet needs is a need for efficacious treatment options for BRAF wild-type patients. Approximately half of melanoma patients do not have BRAF mutations, and are therefore non-eligible for BRAF/MEK inhibitor treatments. Other unmet needs include therapies for PD-1 immunotherapy non-responders, adjuvant treatment for patients with resected melanoma, effective treatment for brain metastasis, and predictive markers for therapeutic response to immunotherapies.

Scope

  • Overview of melanoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized melanoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in six patient segments (including adjuvant, BRAF mutated and BRAF wild-type), forecast from 2013 to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the melanoma therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.
  • Analysis of the current and future market competition in the global melanoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global melanoma therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global melanoma therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Melanoma Biomarkers
  • 3.2. Clinical Staging
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan and Australia
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast for Melanoma (2013-2023)
    • 4.5.1. Diagnosed Incident Cases of Melanoma
    • 4.5.2. Age-Specific Diagnosed Incident Cases of Melanoma
    • 4.5.3. Sex-Specific Diagnosed Incident Cases of Melanoma Skin Cancer
    • 4.5.4. Age-Standardized Diagnosed Incidence Rates
    • 4.5.5. Pathological Stage at Diagnosis
    • 4.5.6. Five-Year Diagnosed Prevalent Cases of Melanoma Skin Cancer
    • 4.5.7. Five-Year Diagnosed Prevalent Cases of Melanoma Skin Cancer by Genetic Aberrations
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis Overview
  • 5.2. Treatment Overview
    • 5.2.1. Localized Melanoma: Stage 0 to Stage IIC
    • 5.2.2. Regional Melanoma: Stage IIIA to Stage IIIC
    • 5.2.3. Unresectable and Metastatic Melanoma: Stage III and Stage IV
  • 5.3. US
    • 5.3.1. Screening and Diagnosis
    • 5.3.2. Clinical Practices
  • 5.4. France
    • 5.4.1. Screening and Diagnosis
    • 5.4.2. Clinical Practices
  • 5.5. Germany
    • 5.5.1. Screening and Diagnosis
    • 5.5.2. Clinical Practices
  • 5.6. Italy
    • 5.6.1. Screening and Diagnosis
    • 5.6.2. Clinical Practices
  • 5.7. Spain
    • 5.7.1. Screening and Diagnosis
    • 5.7.2. Clinical Practices
  • 5.8. UK
    • 5.8.1. Screening and Diagnosis
    • 5.8.2. Clinical Practices
  • 5.9. Japan
    • 5.9.1. Screening and Diagnosis
    • 5.9.2. Clinical Practices
  • 5.10. Australia
    • 5.10.1. Screening and Diagnosis
    • 5.10.2. Clinical Practices

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Interferon-based Adjuvant Therapies
    • 6.2.1. Roferon-A (Interferon Alfa-2a)
    • 6.2.2. Intron A (Interferon Alfa-2b)
    • 6.2.3. Sylatron (Peginterferon Alfa-2b)
  • 6.3. Immune Checkpoint Inhibitors
    • 6.3.1. Yervoy (Ipilimumab)
    • 6.3.2. Opdivo (Nivolumab)
    • 6.3.3. Keytruda (Pembrolizumab)
  • 6.4. BRAF Mutation-targeted Therapies
    • 6.4.1. Zelboraf (Vemurafenib)
    • 6.4.2. Tafinlar (Dabrafenib)
    • 6.4.3. Mekinist (Trametinib)
  • 6.5. Other Therapeutic Classes

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Therapeutic Options for BRAF Wild-Type Patients
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Therapies for Non-responders to PD-1 Immunotherapy
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Adjuvant Therapies for High-Risk Resectable Melanoma
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Effective Treatment for Brain Metastases
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Predictive Markers for Therapeutic Response to Immunotherapies
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
  • 8.3. RAF/RAS/MEK Pathway-Targeting Therapies
    • 8.3.1. Cobimetinib (GDC-0973)
    • 8.3.2. Encorafenib (LGX818)
    • 8.3.3. Binimetinib (MEK162)
  • 8.4. Immune-Related Therapies
    • 8.4.1. Talimogene Laherparepvec
    • 8.4.2. Eltrapuldencel-T (NSB20)
    • 8.4.3. Seviprotimut-L (POL-103A)
    • 8.4.4. PV-10
  • 8.5. Promising Drugs in Early-Stage Development
    • 8.5.1. PI3K/Akt/mTOR Pathway-Targeting Therapies
    • 8.5.2. Cell Cycle Checkpoint Inhibitors
    • 8.5.3. Next-Generation BRAF Inhibitors
    • 8.5.4. Immunotherapies
    • 8.5.5. Antibody-Drug Conjugates
  • 8.6. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Bristol-Myers Squibb
    • 9.3.2. Novartis
    • 9.3.3. Roche
    • 9.3.4. Merck

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers - US
  • 10.3. 5EU
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers - France
    • 10.3.4. Drivers and Barriers - Germany
    • 10.3.5. Drivers and Barriers - Italy
    • 10.3.6. Drivers and Barriers - Spain
    • 10.3.7. Drivers and Barriers - UK
  • 10.4. Japan
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers - Japan
  • 10.5. Australia
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers - Australia

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Melanoma Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Average Body Weight and Surface Area Across the 8MM
    • 11.4.7. Individual Drug Assumptions
    • 11.4.8. Generic Erosion
    • 11.4.9. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Stage Definitions for Melanoma
  • Table 2: The ABCED Rule of Melanoma Detection
  • Table 3: Prognosis of Melanoma
  • Table 4: Risk Factors and Comorbidities for Melanoma of the Skin
  • Table 5: Melanoma of the Skin Staging Definition Equivalencies
  • Table 6: 8MM, Sources of Melanoma of the Skin Incidence Data
  • Table 7: 8MM, Sources of Melanoma of the Skin Incident Cases by Pathological Stage at Diagnosis Data
  • Table 8: 8MM, Sources of Melanoma of the Skin Five-Year Diagnosed Prevalent Cases by Stage Data
  • Table 9: 8MM, Sources of Melanoma of the Skin Diagnosed Prevalent Cases by Genetic Aberration
  • Table 10: 8MM, Diagnosed Incident Cases of Melanoma of the Skin, Both Sexes, Ages ≥20 Years, N, Select Years 2013-2023
  • Table 11: 8MM, Age-Specific Diagnosed Incident Cases of Melanoma of the Skin, N (Row%), 2013
  • Table 12: 8MM, Sex-Specific Diagnosed Incident Cases of Melanoma of the Skin, Ages ≥20 Years, N (Row %), 2013
  • Table 13: Age-Standardized Diagnosed Incidence Rate (ASR) of Melanoma of the Skin, Men and Women, Ages ≥20 Years, 2013
  • Table 14: 8MM, Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin, Both Sexes, ≥20 years, N, Select Years 2013-2023
  • Table 15: Clinical Guidelines for Melanoma
  • Table 16: Most Prescribed Drugs for Melanoma by Class in the Global Markets, 2013
  • Table 17: Country Profile - US
  • Table 18: Country Profile - France
  • Table 19: Country Profile - Germany
  • Table 20: Country Profile - Italy
  • Table 21: Country Profile - Spain
  • Table 22: Country Profile - UK
  • Table 23: Country Profile - Japan
  • Table 24: Country Profile - Australia
  • Table 25: Leading Treatments for Melanoma, 2013
  • Table 26: Product Profile - Roferon-A
  • Table 27: Safety of Roferon-A
  • Table 28: Roferon-A SWOT Analysis, 2015
  • Table 29: Global Sales Forecast ($m) for Roferon-A, 2013-2023
  • Table 30: Product Profile - Intron A
  • Table 31: Efficacy of Intron A (E1684)
  • Table 32: Safety of Intron A (E1684, E1690, and E1694)
  • Table 33: Intron A SWOT Analysis, 2015
  • Table 34: Global Sales Forecast ($m) for Intron A, 2013-2023
  • Table 35: Product Profile - Sylatron
  • Table 36: Efficacy of Sylatron (EORTC 18991, NCT00006249)
  • Table 37: Head-to-Head Comparison Between Sylatron and Low-Dose Interferon
  • Table 38: Safety of Sylatron
  • Table 39: Sylatron SWOT Analysis, 2015
  • Table 40: Global Sales Forecast ($m) for Sylatron, 2013-2023
  • Table 41: Product Profile - Yervoy
  • Table 42: Efficacy of Yervoy
  • Table 43: Comparison of Higher Dose Yervoy and Dacarbazine (NCT00324155)
  • Table 44: Network Meta-analysis of Yervoy
  • Table 45: Safety of Yervoy at 3mg/kg (NCT00094653)
  • Table 46: Safety Data from Yervoy Dose-Escalation Study (NCT00289640)
  • Table 47: Yervoy SWOT Analysis, 2015
  • Table 48: Global Sales Forecast ($m) for Yervoy, 2013-2023
  • Table 49: Product Profile - Opdivo
  • Table 50: Efficacy of Opdivo
  • Table 51: Efficacy of Opdivo in BRAF Wild-Type Advanced Melanoma (NCT01721772)
  • Table 52: Safety Data from Opdivo Dose-Escalation Study (NCT00730639)
  • Table 53: Safety Data from the CheckMate-037 Trial (NCT01721746)
  • Table 54: Opdivo SWOT Analysis, 2015
  • Table 55: Global Sales Forecast ($m) for Opdivo, 2013-2023
  • Table 56: Product Profile - Keytruda
  • Table 57: Efficacy of Keytruda from KEYNOTE-001 (NCT01295827)
  • Table 58: Efficacy of Keytruda from KEYNOTE-002 (NCT01704287)
  • Table 59: Safety of Keytruda
  • Table 60: Keytruda SWOT Analysis, 2015
  • Table 61: Global Sales Forecasts ($m) for Keytruda, 2013-2023
  • Table 62: Product Profile - Zelboraf
  • Table 63: Efficacy of Zelboraf
  • Table 64: Safety of Zelboraf
  • Table 65: Zelboraf SWOT Analysis, 2015
  • Table 66: Global Sales Forecasts ($m) for Zelboraf, 2013-2023
  • Table 67: Product Profile - Tafinlar
  • Table 68: Efficacy of Tafinlar
  • Table 69: Safety of Tafinlar
  • Table 70: Tafinlar SWOT Analysis, 2015
  • Table 71: Global Sales Forecast ($m) for Tafinlar, 2013-2023
  • Table 72: Product Profile - Mekinist
  • Table 73: Efficacy of Mekinist
  • Table 74: Efficacy Results of the COMBI-d Trial (NCT01584648)
  • Table 75: Efficacy Results of the COMBI-v Trial (NCT01072175)
  • Table 76: Safety of Mekinist
  • Table 77: Safety Results of the COMBI-d trial (NCT01584648)
  • Table 78: Safety Results of the COMBI-v trial (NCT01584648)
  • Table 79: Mekinist SWOT Analysis, 2015
  • Table 80: Global Sales Forecasts ($m) for Mekinist, 2013-2023
  • Table 81: Summary of Minor Therapeutic Classes, 2013
  • Table 82: Unmet Needs and Opportunities in Melanoma
  • Table 83: Product Profile - Cobimetinib
  • Table 84: Efficacy of the Zelboraf/Cobimetinib Combination
  • Table 85: Safety of the Zelboraf/Cobimetinib Combination
  • Table 86: Cobimetinib SWOT Analysis, 2015
  • Table 87: Global Sales Forecast ($m) for Cobimetinib, 2013-2023
  • Table 88: Product Profile - Encorafenib
  • Table 89: Efficacy of Encorafenib
  • Table 90: Encorafenib SWOT Analysis, 2015
  • Table 91: Global Sales Forecasts ($m) for Encorafenib, 2013-2023
  • Table 92: Product Profile - Binimetinib
  • Table 93: Efficacy of Binimetinib (NCT01320085)
  • Table 94: Safety of Binimetinib (NCT01320085)
  • Table 95: Binimetinib SWOT Analysis, 2015
  • Table 96: Global Sales Forecasts ($m) for Binimetinib, 2013-2023
  • Table 97: Product Profile - Talimogene Laherparepvec
  • Table 98: Efficacy of Talimogene Laherparepvec
  • Table 99: Safety of Talimogene Laherparepvec
  • Table 100: Talimogene Laherparepvec SWOT Analysis, 2015
  • Table 101: Global Sales Forecast ($m) for Talimogene Laherparepvec, 2013-2023
  • Table 102: Product Profile - Eltrapuldencel-T
  • Table 103: Efficacy of Eltrapuldencel-T
  • Table 104: Eltrapuldencel-T SWOT Analysis, 2015
  • Table 105: Global Sales Forecast ($m) for Eltrapuldencel-T, 2013-2023
  • Table 106: Product Profile - Seviprotimut-L
  • Table 107: Efficacy of Seviprotimut-L
  • Table 108: Seviprotimut-L SWOT Analysis, 2015
  • Table 109: Global Sales Forecast ($m) for Seviprotimut-L, 2013-2023
  • Table 110: Product Profile - PV-10
  • Table 111: Efficacy of PV-10
  • Table 112: Safety of PV-10
  • Table 113: PV-10 SWOT Analysis, 2015
  • Table 114: Global Sales Forecast ($m) for PV-10, 2013-2023
  • Table 115: Clinical Settings of Early-Stage Drugs Targeting the PI3K/Akt/mTOR Pathway
  • Table 116: Clinical Settings of Early-Stage Drugs Targeting Cell Cycle Checkpoints
  • Table 117: Clinical Settings of Early-Stage Next-Generation BRAF Inhibitors
  • Table 118: Clinical Settings of Early-Stage Immunotherapies
  • Table 119: Clinical Settings of Early-Stage Antibody-drug Conjugates
  • Table 120: Drugs in Development, 2015
  • Table 121: Key Companies in the Melanoma Market in the 8MM, 2013-2023
  • Table 122: BMS' Melanoma Portfolio Assessment, 2015
  • Table 123: Novartis' Melanoma Portfolio Assessment, 2015
  • Table 124: Roche's Melanoma Portfolio Assessment, 2015
  • Table 125: Merck's Melanoma Portfolio Assessment, 2015
  • Table 126: Global Sales Forecast ($m) for Melanoma, 2013-2023
  • Table 127: Melanoma Market - Drivers and Barriers, 2015
  • Table 128: Sales Forecast ($m) for Melanoma in the United States, 2013-2023
  • Table 129: Key Events Impacting Sales for Melanoma in the United States, 2013-2023
  • Table 130: Melanoma Market in the United States - Drivers and Barriers, 2015
  • Table 131: Sales Forecast ($m) for Melanoma in the 5EU, 2013-2023
  • Table 132: Key Events Impacting Sales for Melanoma in the 5EU, 2013-2023
  • Table 133: Melanoma Market in France - Drivers and Barriers, 2015
  • Table 134: Melanoma Market in Germany - Drivers and Barriers, 2015
  • Table 135: Melanoma Market in Italy - Drivers and Barriers, 2015
  • Table 136: Melanoma Market in Spain - Drivers and Barriers, 2015
  • Table 137: Melanoma Market in the United Kingdom - Drivers and Barriers, 2015
  • Table 138: Sales Forecast ($m) for Melanoma in Japan, 2013-2023
  • Table 139: Key Events Impacting Sales for Melanoma in Japan, 2013-2023
  • Table 140: Melanoma Market in Japan - Drivers and Barriers, 2015
  • Table 141: Sales Forecast ($m) for Melanoma in Australia, 2013-2023
  • Table 142: Key Events Impacting Sales for Melanoma in Australia, 2013-2023
  • Table 143: Melanoma Market in Australia - Drivers and Barriers, 2015
  • Table 144: Key Launch Dates
  • Table 145: Key Patent Expiries
  • Table 146 Average Body Weight and Surface Area Across the 8MM
  • Table 147: High-Prescribing Physicians Surveyed by Country

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of Melanoma of the Skin, Ages ≥20 Years, Both Sexes, N, 2013-2023
  • Figure 2: Age-Specific Diagnosed Incident Cases of Melanoma of the Skin, Both Sexes, N, 2013
  • Figure 3: Sex-Specific Diagnosed Incident Cases of Melanoma of the Skin (N), 2013
  • Figure 4 : Age-Standardized Diagnosed Incidence Rate (ASR) of Melanoma of the Skin, Men and Women, Ages ≥20 Years, 2013
  • Figure 5: Distribution of Incident Cases of Melanoma Skin Cancer by Stage at Diagnosis (%)
  • Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 7: Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin with BRAF Mutations, Both Sexes, Ages ≥20 Years, N, 2013
  • Figure 8: Five-Year Diagnosed Prevalent Cases of Melanoma of the Skin with NRAS Mutations, Both Sexes, Ages ≥20 Years, 2013
  • Figure 9: Treatment Flowchart for Localized Melanoma
  • Figure 10: Treatment Flowchart for Regional Melanoma
  • Figure 11: Treatment Flowchart for Recurrent Melanoma
  • Figure 12: Treatment Flowchart for Metastatic Melanoma
  • Figure 13: Yervoy's Development in Melanoma
  • Figure 14: Opdivo's Development in Melanoma
  • Figure 15: Keytruda's Development in Melanoma
  • Figure 16: Zelboraf's Development in Melanoma
  • Figure 17: Mekinist's Development in Melanoma
  • Figure 18: Melanoma - Phase III Pipeline, 2015
  • Figure 19: Competitive Assessment of Late-Stage Pipeline Agents in Melanoma, 2013-2023
  • Figure 20: Cobimetinib's Development in Melanoma
  • Figure 21: Clinical and Commercial Positioning of Cobimetinib
  • Figure 22: Encorafenib's Development in Melanoma
  • Figure 23: Clinical and Commercial Positioning of Encorafenib
  • Figure 24: Binimetinib's Development in Melanoma
  • Figure 25: Clinical and Commercial Positioning of Binimetinib
  • Figure 26: Talimogene Laherparepvec's Development in Melanoma
  • Figure 27: Clinical and Commercial Positioning of Talimogene Laherparepvec
  • Figure 28: Eltrapuldencel-T's Development in Melanoma
  • Figure 29: Clinical and Commercial Positioning of Eltrapuldencel-T
  • Figure 30: Seviprotimut-L's Development in Melanoma
  • Figure 31: Clinical and Commercial Positioning of Seviprotimut-L
  • Figure 32: PV-10's Development in Melanoma
  • Figure 33: Clinical and Commercial Positioning of PV-10
  • Figure 34: Global Sales of Branded Products for Melanoma by Company, 2013-2023
  • Figure 35: Company Portfolio Gap Analysis in Melanoma, 2013-2023
  • Figure 36: Bristol-Myers Squibb SWOT Analysis in Melanoma, 2013-2023
  • Figure 37: Novartis SWOT Analysis in Melanoma, 2013-2023
  • Figure 38: Roche SWOT Analysis in Melanoma, 2013-2023
  • Figure 39: Merck SWOT Analysis in Melanoma, 2013-2023
  • Figure 40: Global Sales for Melanoma by Region, 2013-2023
  • Figure 41: Sales for Melanoma in the United States by Drug Class, 2013-2023
  • Figure 42: Sales for Melanoma in the EU by Drug Class, 2013-2023
  • Figure 43: Sales for Melanoma in Japan by Drug Class, 2023
  • Figure 44: Sales for Melanoma in Australia by Drug Class, 2013-2023
Back to Top